ArticleBlood2006
More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).
Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Article
- [The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Impact ofBiology · 2022Article
- DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia.Blood advances · 2021Article
- Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.Scientific reports · 2021Article
- FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.Molecular oncology · 2021Article
- De novo adult acute myeloid leukemia with two new mutations in juxtatransmembrane domain of the FLT3 gene: a case report.Journal of medical case reports · 2021Article
- Impact ofHaematologica · 2019Article
- Clinical implications of molecular markers in acute myeloid leukemia.European journal of haematology · 2019Review
- Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.Cancer science · 2018Article
- Clonal heterogeneity ofOncotarget · 2018Article
- FLT3-ITD and its current role in acute myeloid leukaemia.Medical oncology (Northwood, London, England) · 2017Review
- [The clinical efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combin ation with CHAG regimen].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- [ITD mutation burden for the prognosis in FLT3-ITD positive acute myeloid leukemia patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.Expert review of hematology · 2014Review
- FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.Leukemia & lymphoma · 2014Review
- The Biology and Targeting of FLT3 in Pediatric Leukemia.Frontiers in oncology · 2014Review
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.American journal of hematology · 2011Article
- Review
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
16790588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.